Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
192 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) - The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects - The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Keratoconjunctivitis sicca (Dry Eye) Overview 9 Therapeutics Development 10 Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10 Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21 Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 25 Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 26 AB2 Bio Ltd. 26 Allergan Plc 27 Ascendia Pharmaceuticals LLC 28 Chong Kun Dang Pharmaceutical Corp. 29 Digna Biotech, S.L. 30 Dompe Farmaceutici S.p.A. 31 HanAll Biopharma Co., Ltd. 32 Herantis Pharma Plc 33 Huons Co., Ltd. 34 InSite Vision Incorporated 35 Kala Pharmaceuticals, Inc. 36 Kissei Pharmaceutical Co., Ltd. 37 KPI Therapeutics, Inc. 38 Kukje Pharmaceutical Industry Co., Ltd. 39 Laboratoires Thea S.A. 40 Lee's Pharmaceutical Holdings Limited 41 Lipicard Technologies Limited 42 Merck & Co., Inc. 43 Mimetogen Pharmaceuticals Inc. 44 Mitotech S.A. 45 Nanomerics Ltd 46 Neuroptis Biotech 47 Novaliq GmbH 48 Ocular Therapeutix, Inc. 49 Oculis ehf 50 OncoNOx ApS 51 Otsuka Holdings Co., Ltd. 52 Parion Sciences, Inc. 53 Quorum Innovations LLC 54 RegeneRx Biopharmaceuticals, Inc. 55 Rigel Pharmaceuticals, Inc. 56 Samjin Pharmaceutical Co., Ltd. 57 Santen Pharmaceutical Co., Ltd. 58 Seikagaku Corporation 59 Sucampo Pharmaceuticals, Inc. 60 TearSolutions, LLC. 61 TopiVert Ltd 62 Xigen SA 63 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 64 Assessment by Monotherapy Products 64 Assessment by Target 65 Assessment by Mechanism of Action 69 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 AGN-223575 - Drug Profile 77 AGN-232411 - Drug Profile 78 Androgen Tears - Drug Profile 79 AVA-3486 - Drug Profile 80 AVX-012 - Drug Profile 81 BRM-421 - Drug Profile 82 cinhyaluronate sodium - Drug Profile 83 Cis-Urocanic Acid - Drug Profile 84 cyclosporine - Drug Profile 87 cyclosporine - Drug Profile 90 cyclosporine - Drug Profile 92 cyclosporine - Drug Profile 93 cyclosporine - Drug Profile 94 cyclosporine - Drug Profile 95 cyclosporine - Drug Profile 96 cyclosporine - Drug Profile 97 cyclosporine SR - Drug Profile 98 dexamethasone acetate SR - Drug Profile 99 diclofenac sodium - Drug Profile 104 diquafosol tetrasodium - Drug Profile 105 disitertide - Drug Profile 107 Drugs to Agonize FPR2 for Dry Eye - Drug Profile 109 Elate Ocular - Drug Profile 110 HL-036 - Drug Profile 111 HU-007 - Drug Profile 112 hyaluronate sodium - Drug Profile 113 ISV-101 - Drug Profile 114 K-089 - Drug Profile 115 KeraKlear - Drug Profile 116 KJ-14003 - Drug Profile 117 KL-7016 - Drug Profile 118 KPI-190 - Drug Profile 119 Lacripep - Drug Profile 120 LME-636 - Drug Profile 121 loteprednol etabonate - Drug Profile 122 LT-4002 - Drug Profile 125 LT-4003 - Drug Profile 126 NOP-3 - Drug Profile 127 NOP-5 - Drug Profile 128 Nov-03 - Drug Profile 129 OC-301 - Drug Profile 130 OX-1001 - Drug Profile 131 ozagrel - Drug Profile 132 P-321 - Drug Profile 133 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 135 PPL-003 - Drug Profile 137 Qi-204 - Drug Profile 139 R-348 - Drug Profile 140 rebamipide - Drug Profile 142 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 144 RGN-259 - Drug Profile 146 RP-101 - Drug Profile 153 RU-101 - Drug Profile 154 SA-001 - Drug Profile 156 SJP-002 - Drug Profile 157 Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 158 ST-266 - Drug Profile 159 tadekinig alfa - Drug Profile 161 tavilermide hydrochloride - Drug Profile 162 TOP-1630 - Drug Profile 164 XG-104 - Drug Profile 165 ZK-003 - Drug Profile 166 zucapsaicin - Drug Profile 167 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 175 Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 187 Methodology 187 Coverage 187 Secondary Research 187 Primary Research 187 Expert Panel Validation 187 Contact Us 187 Disclaimer 188
List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016 14 Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Development by Companies, H2 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016 30 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016 31 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 32 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 33 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016 34 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 35 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 36 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016 37 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016 38 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016 39 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 40 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 41 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016 42 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 43 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016 44 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 45 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016 46 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016 47 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016 48 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016 49 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016 50 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016 51 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016 52 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016 53 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016 54 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016 55 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 56 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016 57 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016 58 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 59 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 60 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016 61 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 62 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016 63 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 64 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016 65 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016 66 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016 67 Assessment by Monotherapy Products, H2 2016 68 Number of Products by Stage and Target, H2 2016 70 Number of Products by Stage and Mechanism of Action, H2 2016 74 Number of Products by Stage and Route of Administration, H2 2016 78 Number of Products by Stage and Molecule Type, H2 2016 80 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016 173 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016 174 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016 175 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016 176 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016 177 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016 178 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
